NO994858L - Compounds and preparations for the treatment of diseases associated with serine protease, especially tryptase activity - Google Patents

Compounds and preparations for the treatment of diseases associated with serine protease, especially tryptase activity

Info

Publication number
NO994858L
NO994858L NO994858A NO994858A NO994858L NO 994858 L NO994858 L NO 994858L NO 994858 A NO994858 A NO 994858A NO 994858 A NO994858 A NO 994858A NO 994858 L NO994858 L NO 994858L
Authority
NO
Norway
Prior art keywords
preparations
compounds
treatment
serine protease
diseases associated
Prior art date
Application number
NO994858A
Other languages
Norwegian (no)
Other versions
NO314183B1 (en
NO994858D0 (en
Inventor
Timothy J Church
Neil Scott Cutshall
Anthony R Gangloff
Thomas E Jenkins
Martin S Linsell
Joane Litvak
Kenneth D Rice
Jeffrey R Spencer
Vivian Rueywen Wang
Original Assignee
Axys Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axys Pharm Corp filed Critical Axys Pharm Corp
Publication of NO994858D0 publication Critical patent/NO994858D0/en
Publication of NO994858L publication Critical patent/NO994858L/en
Publication of NO314183B1 publication Critical patent/NO314183B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19994858A 1997-04-07 1999-10-06 Benzimidazole derivatives, their use and pharmaceutical preparations containing them NO314183B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83367497A 1997-04-07 1997-04-07
PCT/US1997/021849 WO1998045275A1 (en) 1997-04-07 1997-12-01 Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, activity

Publications (3)

Publication Number Publication Date
NO994858D0 NO994858D0 (en) 1999-10-06
NO994858L true NO994858L (en) 1999-12-06
NO314183B1 NO314183B1 (en) 2003-02-10

Family

ID=25264996

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19994858A NO314183B1 (en) 1997-04-07 1999-10-06 Benzimidazole derivatives, their use and pharmaceutical preparations containing them

Country Status (16)

Country Link
EP (1) EP1019382A1 (en)
JP (1) JP2001519806A (en)
KR (1) KR20010006119A (en)
CN (1) CN1251579A (en)
AU (1) AU752064B2 (en)
CA (1) CA2285454A1 (en)
EE (1) EE04055B1 (en)
HU (1) HUP0001522A3 (en)
LT (1) LT4704B (en)
LV (1) LV12495B (en)
NO (1) NO314183B1 (en)
NZ (1) NZ500029A (en)
PL (1) PL336233A1 (en)
SI (1) SI20115A (en)
SK (1) SK136799A3 (en)
WO (1) WO1998045275A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
WO1999026933A1 (en) * 1997-11-26 1999-06-03 Axys Pharmaceuticals, Inc. Substituted amidinoaryl derivatives and their use as anticoagulants
WO1999026932A1 (en) * 1997-11-26 1999-06-03 Axys Pharmaceuticals, Inc. By amidino group substituted heterocyclic derivatives and their use as anticoagulants
GT199900167A (en) * 1998-10-01 2001-03-21 NEW BIS-BENZIMIDAZOLES.
WO2000020400A1 (en) * 1998-10-05 2000-04-13 Axys Pharmaceuticals, Inc. Novel compounds and compositions for treating hepatitis c infections
ATE256666T1 (en) * 1999-06-04 2004-01-15 Elan Pharma Int Ltd COMPOSITIONS AND METHODS FOR PREVENTING CELL DEATH
DE19953899A1 (en) * 1999-11-10 2001-05-17 Boehringer Ingelheim Pharma Carboxamide-substituted benzimidazole derivatives, process for their preparation and their use as medicaments
WO2001052883A1 (en) * 2000-01-20 2001-07-26 Amgen Inc. Inhibitors of protease-activated receptor-2 (par-2) as novel asthma therapeutics
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
DE10048715A1 (en) * 2000-09-30 2004-05-19 Grünenthal GmbH Use of amino acid for the treatment of pain
JP4176477B2 (en) * 2001-03-01 2008-11-05 塩野義製薬株式会社 Nitrogen-containing aromatic heterocyclic derivatives having HIV integrase inhibitory activity
GB0406282D0 (en) * 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
DE102011111991A1 (en) 2011-08-30 2013-02-28 Lead Discovery Center Gmbh New cyclosporin derivatives
AP2014007662A0 (en) * 2011-11-29 2014-05-31 Perosphere Inc Anticoagulant reversal agents
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
JP7318009B2 (en) * 2019-05-21 2023-07-31 浙江海正薬業股▲ふん▼有限公司 Macrolide derivative, production method and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3105837A (en) * 1961-10-20 1963-10-01 Upjohn Co 2, 2'-alkylenebisbenzimidazoles
US3210370A (en) * 1964-06-22 1965-10-05 Upjohn Co Process for preparing 2, 2'-methylene-bisareneimiazoles
HUT71345A (en) * 1993-09-22 1995-11-28 Wellcome Found Bis(amidinobenzimidazolyl)alkanes and pharmaceutical compositions containing them
US6815461B1 (en) * 1994-01-20 2004-11-09 The University Of North Carolina At Chapel Hill Method of inhibiting retroviral integrase
US5693515A (en) * 1995-04-28 1997-12-02 Arris Pharmaceutical Corporation Metal complexed serine protease inhibitors

Also Published As

Publication number Publication date
HUP0001522A2 (en) 2001-05-28
SI20115A (en) 2000-06-30
SK136799A3 (en) 2000-07-11
EE04055B1 (en) 2003-06-16
EP1019382A1 (en) 2000-07-19
KR20010006119A (en) 2001-01-26
AU5895098A (en) 1998-10-30
CN1251579A (en) 2000-04-26
CA2285454A1 (en) 1998-10-15
NZ500029A (en) 2001-02-23
JP2001519806A (en) 2001-10-23
NO314183B1 (en) 2003-02-10
PL336233A1 (en) 2000-06-19
AU752064B2 (en) 2002-09-05
LV12495B (en) 2001-01-20
LV12495A (en) 2000-06-20
LT4704B (en) 2000-09-25
NO994858D0 (en) 1999-10-06
LT99131A (en) 2000-04-25
HUP0001522A3 (en) 2001-08-28
WO1998045275A1 (en) 1998-10-15
EE9900477A (en) 2000-06-15

Similar Documents

Publication Publication Date Title
NO994858L (en) Compounds and preparations for the treatment of diseases associated with serine protease, especially tryptase activity
BR9712544B1 (en) SERINE PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITION UNDERSTANDING THE SAME AND ITS USES
NO994613D0 (en) Procedures and preparations for the treatment of sleep apnea
NO986089D0 (en) Methods and preparations for the treatment of tumors, tumor-related diseases and o
NO20002835L (en) 2-aryl-oxodihydropurine derivatives, process for the preparation of these medicinal preparations containing them, and intermediates therefor
ATE447947T1 (en) PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF INSULINRESIENCE
EE9900036A (en) Novel compounds and compositions for the treatment of diseases associated with tryptase activity
EE04156B1 (en) Sulfonamides for the treatment of endothelin-mediated diseases
EE200300214A (en) Sulfonamides for the treatment of endothelin-mediated diseases
ATE417602T1 (en) AGENTS FOR THE TREATMENT OF DISEASES OF THE ESOPHAUS
NO20004098D0 (en) Methods and preparations for the treatment of macrophage-mediated disorders
DK0979240T3 (en) serine protease
PL343373A1 (en) Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily
NO20013507L (en) Preparations for the treatment of inflammatory reactions
AU7471598A (en) Human serine protease precursor
NO991459D0 (en) Use of 1-hydroxy-2-pyridones for the treatment of skin infections
NO20003229L (en) Combination of benzocycloheptapyridine compounds and antineoplastic agents for the treatment of proliferative diseases
IT1290781B1 (en) ACTIVE THERAPEUTIC AGENT FOR THE TREATMENT OF NEURONAL DEGENERATIVE DISEASES.
PT900563E (en) PRODUCTION OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF EDEMA AND VENOUS DISEASES
DE3884145D1 (en) 4H-3,1-BENZOXAZINE-4-ON COMPOUNDS AND SERINE PROTEASE INHIBITING MEDICINAL PRODUCTS.
GB9929497D0 (en) Improved amino acid mixtures for the treatment and/or management of certain diseases
DK199901456A (en) Serine protease and topical retonoid preparations
HUP0000785A3 (en) Ointment for the treatment of burns and other skin diseases
NO20004920D0 (en) Use of protease inhibitors for the treatment of skin damage
ZA200110539B (en) Oxazinocarbazoles for the treatment of CNS diseases.